Final answer:
Carbapenems are not easily inactivated by ESBLs produced by certain Gram-negative bacteria, so they can be used to treat these infections.
Step-by-step explanation:
False. Carbapenems are not easily inactivated by the extended-spectrum β-lactamases (ESBLs) produced by certain Gram-negative bacteria. ESBLs provide resistance to all penicillins, cephalosporins, monobactams, and ß-lactamase-inhibitor combinations, but not carbapenems.
The carbapenems are a group of drugs that provide very broad-spectrum activity against both gram-positive and gram-negative bacterial pathogens and are often used to treat infections caused by ESBL-producing bacteria.